Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Alcon reported third quarter sales of $2.1 billion, a 15% increase year-over-year, reflecting growth across all Surgical and Vision Care segments. The company achieved a core diluted EPS of $0.54, and a core operating margin of 17.7%. Cash flow from operations reached $958 million, with free cash flow at $578 million. Alcon plans to expand in the surgical glaucoma market through the intended acquisition of Ivantis. Despite a net debt position of $2.5 billion, the company ended the quarter with a cash balance of $1.6 billion.
Alcon (NYSE: ALC) reported a strong performance for Q3 and the first nine months of 2021, with sales reaching $2.1 billion, a 15% increase compared to the same period in 2020. Key segments, Surgical and Vision Care, showed significant growth, benefiting from innovation and market recovery post-pandemic. Cash from operations totaled $958 million, with free cash flow at $578 million. Alcon is expanding its surgical glaucoma offerings through an intended acquisition of Ivantis, highlighting its commitment to innovation.
Alcon has introduced SMART Solutions, a digital platform for ophthalmology, furthering its leadership in integrated surgical technologies. The application SMARTCataract is now being installed with U.S. customers, enhancing clinic-to-OR connectivity with cloud-based planning. With access to data from more than 2 million cases through the ORA SYSTEM, surgical accuracy and efficiency are emphasized. Alcon aims for broader rollout in 2022, showcasing advancements at the American Academy of Ophthalmology meeting.
Alcon (NYSE: ALC) has announced its intention to acquire Ivantis, the maker of the Hydrus Microstent, a minimally invasive glaucoma surgery device. The acquisition, valued at $475 million, aims to strengthen Alcon's surgical glaucoma portfolio. The Hydrus Microstent has shown a strong safety profile in a five-year study, with 65% of patients remaining medication-free. This acquisition seeks to expand access to effective glaucoma treatments worldwide, addressing a significant unmet patient need. The transaction is expected to close in the first quarter of 2022, pending regulatory approval.
Alcon will showcase its innovative TOTAL30 contact lenses at the American Academy of Optometry Annual Meeting in Boston from November 3-6, 2021. The TOTAL30 lens, featuring Water Gradient technology, is designed for comfort, even at day 30 of wear. Alongside the launch, Alcon will present clinical data supporting its product portfolio, including DAILIES TOTAL1 for Astigmatism and updates to its dry eye range. The event will include hands-on experiences, scientific presentations, and new product previews aimed at enhancing patient and professional satisfaction.
Summary not available.
Alcon, a leader in eye care, has won the FutureEdge 50 Award for its ForeSight enterprise data and analytics platform, recognizing its innovative approach to technology. This platform, developed in just 67 days, played a crucial role in Alcon's transition to an independent company by separating IT services from its former parent. The award underscores Alcon's commitment to cost and time savings while establishing its leadership in data analytics. This achievement follows multiple accolades for the company in 2021, including the CIO of the Year ORBIE Award.
Alcon reported strong financial results for Q2 2021, with worldwide sales reaching $2.1 billion, a 75% increase year-over-year. Diluted earnings per share were $0.31, with core diluted earnings at $0.56. Surgical net sales surged 100% and Vision Care sales increased 49%. The company raised its full-year sales outlook to $8.0 to $8.2 billion. Operating income for Q2 was $229 million, significantly improved from last year. Alcon's cash position was $1.4 billion, with a net debt of $2.8 billion.
Alcon (NYSE: ALC) announced the launch of TOTAL30®, a revolutionary monthly replacement Water Gradient contact lens. This lens offers unparalleled comfort, feeling like nothing even on day 30. The reusable lens segment represents 45% of the $9 billion global contact lens market. TOTAL30 integrates new CELLIGENT™ Technology, enhancing durability and reducing bacteria adhesion. Set for U.S. release in September 2021, it aims to meet the needs of the two-thirds of contact lens wearers who prefer reusable options, addressing a decade-long innovation gap in this segment.
Alcon (SIX/NYSE: ALC) will present over 60 abstracts at the ASCRS 2021 meeting in Las Vegas, focusing on its ophthalmic products, particularly presbyopia-correcting intraocular lenses (IOLs) like AcrySof® Vivity™ IQ, AcrySof® PanOptix®, and Clareon® IOL. Key findings show Vivity IOL achieves 94% distance vision without glasses and 90% patient satisfaction. Presentations will also cover innovations such as the ARGOS® biometer and NGENUITY® 3D visualization system, demonstrating Alcon's commitment to surgical efficiency and patient outcomes in cataract procedures.